

CLAIMS:

1. (Currently Amended) A method of treating an intestinal damage comprising administering a pharmaceutically active formulation of PYY or a PYY agonist to a ~~patient in need thereof~~ subject to treat the intestinal damage.
2. (Currently Amended) The method of claim 1 wherein the intestinal damage is associated with a condition selected from the group consisting of inflammatory bowel disease, bowel atrophy, loss of bowel mucosa, and loss of bowel mucosal function.
3. (Previously Presented) The method of claim 2 wherein the inflammatory bowel disease is ulcerative colitis.
4. Canceled.
5. (New) The method of claim 1 wherein the intestinal damage is caused by an event selected from the group consisting of exposure to cytotoxic agents, radiation, toxicity, infection and an injury.
6. (New) The method of claim 1 wherein the PYY or the PYY agonist is used in conjunction with a cytotoxic agent or radiation.
7. (New) The method of claim 1 further comprising administering a growth hormone.
8. (New) The method of claim 1 further comprising administering an anti-inflammatory agent.
9. (New) The method of claim 8 wherein the anti-inflammatory agent is selected from the group consisting of tacrolimus, mycophenolate mofetil, anti-tumor necrosis factor antibody, interleukin-10, interleukin-11, anti-interleukin-12 antibody, anti-interleukin-1 antibody, anti-alpha4 integrin antibody, and nicotine.

10. (New) The method of claim 1 wherein the PYY or the PYY agonist is administered by a route selected from the group consisting of intravenous, intraperitoneal, subcutaneous, intramuscular, oral, rectal, topical, transmucosal, nasal, or pulmonary inhalation.
11. (New) The method of claim 1 wherein the PYY or the PYY agonist is administered in the amount of about 100 µg to about 500 mg/day.
12. (New) The method of claim 1 wherein the PYY or the PYY agonist is administered in the amount of about 500 µg to 100 mg/day.
13. (New) The method of claim 1 wherein the subject is a human.
14. (New) The method of claim 1 wherein the PYY agonist is PYY[3-36].
15. (New) A probiotic bacterium comprising a nucleic acid encoding PYY or a PYY agonist.
16. (New) The probiotic bacterium of claim 15 wherein the bacteria expresses and secretes the PYY or the PYY agonist.
17. (New) The probiotic bacterium of claim 15 wherein the bacterium is a lactobacillus bacterium.
18. (New) The probiotic bacterium of claim 15 wherein the PYY agonist is PYY[3-36].
19. (New) A method of treating a bowel condition comprising administering the probiotic bacterium of claim 15 to a patient.
20. (New) The method of claim 19 wherein the probiotic bacterium is administered by oral ingestion or suppository.
21. (New) The method of claim 19 wherein the bowel condition comprises intestinal damage.

REMARKS

Claim 4 has been canceled without prejudice. New claims 5-21 have been added.

Support for new claims 5 and 6 can be found at least at page 4, lines 14-18.

Support for new claim 7 can be found at least in originally filed claim 13.

Support for new claim 8 can be found at least in originally filed claim 11.

Support for new claim 9 can be found at least in originally filed claim 12.

Support for new claim 10 can be found at least at page 12, lines 22-24.

Support for new claims 11 and 12 can be found at least at page 14, lines 21-23.

Support for new claim 13 can be found at least at page 15, lines 7-8.

Support for new claim 14 can be found at least at page 6, line 20.

Support for new claims 15-21 can be found at least at page 6, lines 13-18.